Radiopharm Theranostics Ltd
Radiopharm Theranostics Ltd (RDPTF): 1 pipeline candidate. Updated within the last hour.
BioSniper Score
2-factor signal · derived from public data
N/A
N/A
Lead: Phase 1/Phase 2
1 candidate
N/A
N/A
A transparent, data-derived signal for Radiopharm Theranostics Ltdacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$47.3M
Cash
—
Quarterly Burn
—
Runway
—
Revenue
—
Pipeline (1 candidate)
| Drug | Phase |
|---|---|
| 161tb rad402 | Phase 1/Phase 2 |
Frequently asked questions
How many drug candidates are in Radiopharm Theranostics Ltd's pipeline?
Radiopharm Theranostics Ltd (RDPTF) has 1 pipeline candidate tracked by BioSniper across SEC filings and clinical trial registrations.
What is Radiopharm Theranostics Ltd's lead drug candidate?
Radiopharm Theranostics Ltd's most advanced tracked candidate is 161tb rad402 (Phase 1/Phase 2) for Castration-resistant Prostate Cancer.
What is Radiopharm Theranostics Ltd's market capitalization?
Radiopharm Theranostics Ltd's market capitalization is approximately $47.3M.
Who is the CEO of Radiopharm Theranostics Ltd?
Mr. Riccardo Canevari is the chief executive officer of Radiopharm Theranostics Ltd (RDPTF).
Get the full picture on Radiopharm Theranostics Ltd
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.